At a glance
ClinicalIndex Comparison Record- ✓Pregnant women presenting on their first visit to the hospital
- ✓Age 18 years or older
- ✓Willing to participate and provide informed consent
- ✕Systemic or topical vaginal antibiotic use within 2 weeks prior to first perinatal visit
- ✕Comorbidities known to be related to adverse pregnancy outcomes, such as diabetes or hypertension
- ✕Diagnosed adverse pregnancy outcomes at recruitment, e.g., stillbirth
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Genital Chlamydia Trachomatis Treatment to Pregnant Women to Prevent Adverse Pregnancy Outcomes: A Randomized Control Trial Pilot Study
In Brief
A clinical study evaluating C. trachomatis and N. gonorrhoeae, Azithromycin, and 1 other intervention for Chlamydia Trachomatis Infection. Completed, enrolled 200 participants across 2 sites.
Detailed Summary
This study aims to identify the relationship between genital C. trachomatis and adverse pregnancy outcomes, and investigate whether screening and treatment of genital C. trachomatis in pregnant women can reduce adverse pregnancy outcomes. Approximately 200 pregnant women from Nanhai Hospital of Southern Medical University in Guangzhou, China will be enrolled and randomized to the intervention or control group.
Study Details
Timeline
Interventions
In vitro nucleic acid amplification test for the qualitative detection of Chlamydia trachomatis and/or Neisseria gonorrhea in patient specimens utilizing amplification of target DNA by the Polymerase Chain Reaction (PCR) and nucleic acid hybridization for the detection of C. trachomatis and N. gonorrhoeae.
Azithromycin 1g administered as a single oral dose
Pregnant women who test positive for Chlamydia will also be suggested to take Azithromycin home to treat their spouses